RxDoctor Payments Data

Steven Sawelson, MD

Nephrology · Torrance, CANPI 1740354034

Payments from drug & device makers

$5,618in general payments, 2019–2025

Across 241 payments — averaging $23.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$885
  • Boehringer Ingelheim$605
  • Bayer$578
  • AstraZeneca$540
  • Gastroklenz, Inc. DBA Cloudcath$400
  • Amgen$328
  • plus $2K from 19 others

What the payments were for

  • Speaking & faculty fees$4007%
  • Food & beverage$5,08691%
  • Education$1322%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,618 in reported general payments places this provider in the 70th percentile of 1,341 nephrology providers in California.

See all nephrology providers in California

Medicare billing

Part B allowed, 2024
$141,162
Medicare patients
325
Services billed
1,015

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol402$313,256
KerendiaFinerenone169$128,082
ProcritEpoetin Alfa23$37,022
LokelmaSodium Zirconium Cyclosilicate43$30,784
JardianceEmpagliflozin30$23,828
JanuviaSitagliptin Phosphate20$21,576
EliquisApixaban24$21,497
VeltassaPatiromer Calcium Sorbitex15$16,455
Sevelamer Carbonate56$16,143
DapagliflozinDapagliflozin Propanediol22$11,684
Repatha SureclickEvolocumab11$10,921
Clonidine15$2,573
Febuxostat13$2,056
Losartan Potassium137$1,936
Allopurinol158$1,599

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$540$344,040445 claims
BayerKerendia$578$128,082169 claims
Boehringer IngelheimJardiance$605$23,82830 claims
MerckJanuvia$67$21,57620 claims
ANI Pharmaceuticals, Inc.Valsartan$50$1,46853 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,341 nephrology providers in California.

Other nephrology in Torrance

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →